Bacil Pharma Financials

BSE: 524516

₹13.89

₹0.66 (4.99%)

As on 02-Sep-2026IST

Market cap

₹20 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

30.3

P/B Ratio

0.8

Div. Yield

0 %

Annual
Quarterly

Income Statement (₹ Cr)	TTM	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Operating Revenue	--	--	--	--	--	--
Total Income	0.32	0.66	0.13	0.11	0.06	0.07
Total Expenditure	0.16	0.25	0.19	0.21	3.91	0.30
EBITDA	-0.16	-0.25	-0.19	-0.21	-3.91	-0.30
Depreciation	--	0.00	0.00	0.00	0.00	0.00
EBIT	-0.16	-0.25	-0.19	-0.22	-3.92	-0.31
Interest	--	--	0.00	0.00	0.00	0.00
Other Income	0.32	0.66	0.13	0.11	0.06	0.07
Exceptional Items	--	--	--	--	--	--
Profit before Tax	0.16	0.41	-0.06	-0.10	-3.86	-0.24
Provision for Tax	-0.50	0.00	--	--	0.00	0.00
Profit after Tax	0.66	0.40	-0.06	-0.10	-3.86	-0.24

Liabilities (₹ Cr)	TTM	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Shareholder's Funds	24.81	25.43	1.21	1.10	1.22	1.39
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	-0.05	-0.06	-0.12	-0.11	-0.11
Current Liabilities	2.58	0.17	0.11	0.03	0.05	2.70
Total Liabilities	27.39	25.60	1.33	1.13	1.27	4.09

Assets (₹ Cr)	TTM	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Non-Current Assets	25.64	22.64	1.22	0.78	0.85	3.68
Current Assets	1.75	2.91	0.05	0.23	0.32	0.30
Total Assets	27.39	25.60	1.33	1.13	1.27	4.09
Total Debt*	--	0.16	0.10	0.02	0.03	0.18
Net Current Assets	-0.83	2.74	-0.06	0.20	0.27	-2.39
Contingent Liabilities	--	--	--	--	--	--

Cashflow (₹ Cr)	TTM	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Cash From Operating Activities	--	0.40	0.00	-0.15	-4.01	-0.40
Cash Flow from Investing Activities	--	0.34	0.08	-0.12	3.81	0.53
Cash from Financing Activities	--	2.08	-0.06	0.06	0.33	-0.07
Net Cash Inflow / Outflow	--	2.82	0.01	-0.20	0.13	0.06

Financials Ratios	TTM	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Adjusted EPS (₹)	0.46	0.30	-0.10	-0.17	-6.55	-0.41
Cash EPS (₹)	0.46	0.30	-0.10	-0.17	-6.55	-0.40
Adjusted Book Value (₹)	17.54	18.60	0.98	0.78	1.00	1.28
Dividend per Share (₹)	--	--	--	--	--	--
Cash Flow per Share (₹)	--	0.30	0.00	-0.25	-6.81	-0.68
Free Cash Flow per Share (₹)	--	0.32	0.04	-0.20	-6.71	-0.43

Profitability Ratios	TTM	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
ROCE (%)	--	3.03	-4.80	-8.45	-273.27	-15.05
ROE (%)	2.57	3.19	-11.38	-19.42	-575.48	-31.82
ROA (%)	2.48	3.01	-5.18	-9.37	-150.07	-6.06
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	204.98	61.11	-45.29	-88.92	-6,704.78	-323.61
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	68.20	-34.36	12.14	94.51	-1,167.86	31.19
Net Profit Growth (%)	-56.02	783.93	42.00	97.36	-1,513.41	24.10
EPS Growth (%)	-68.32	402.29	42.02	97.36	-1,513.29	24.10
Book Value Growth (%)	--	4,204.55	24.59	-21.28	-22.14	0.63

Valuation Ratios	TTM	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Price / Earnings	30.30	140.14	--	--	--	--
Price / Book Value	0.79	2.28	14.96	6.98	5.75	2.44
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	119.56	132.15	-154.07	-32.95	-0.82	-8.32
Close Price (₹)	39.99	42.49	14.63	5.48	5.73	3.12
High Price (₹)	61.80	62.56	14.63	9.68	9.55	6.12
Low Price (₹)	26.69	14.85	4.68	3.67	3.27	1.57
Market Cap (₹ Cr)	19.94	--	--	--	--	--

Solvency Ratios	TTM	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Debt to Equity	--	0.01	0.08	0.02	0.03	0.13
Short term debt to equity ratio	--	0.01	0.08	0.02	0.03	0.13
Current Ratio	0.68	17.21	0.46	8.20	6.69	0.11
Quick Ratio	0.68	17.21	0.46	8.20	6.69	0.11
Interest Coverage	--	--	-83.43	-66.93	-4,517.88	-50.34

Operating Efficiency Ratios	TTM	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.